protein

Human Bone Morphogenetic protein-2 Recombinant

MBS553031

0.01 mg

220 USD

Recombinant Protein

Human Bone Morphogenetic protein-2 Recombinant

Bone Morphogenetic protein-2

bmp2; bone morphogenetic protein; bmp-2

bone morphogenetic protein 2 preproprotein; Bone morphogenetic protein 2; Bone morphogenetic protein 2A

BMP-2

BMP2; BMP2A; BMP-2; BMP-2A

BMP2_HUMAN

E Coli

396

MVAGTRCLLA LLLPQVLLGG AAGLVPELGR RKFAAASSGR PSSQPSDEVL SEFELRLLSM FGLKQRPTPS RDAVVPPYML DLYRRHSGQP GSPAPDHRLE RAASRANTVR SFHHEESLEE LPETSGKTTR RFFFNLSSIP TEEFITSAEL QVFREQMQDA LGNNSSFHHR INIYEIIKPA TANSKFPVTR LLDTRLVNQN ASRWESFDVT PAVMRWTAQG HANHGFVVEV AHLEEKQGVS KRHVRISRSL HQDEHSWSQI RPLLVTFGHD GKGHPLHKRE KRQAKHKQRK RLKSSCKRHP LYVDFSDVGW NDWIVAPPGY HAFYCHGECP FPLADHLNST NHAIVQTLVN SVNSKIPKAC CVPTELSAIS MLYLDENEKV VLKNYQDMVV EGCGCR

>95%, as determined by SDS-PAGE and HPLC

Recombinant Human Bone Morphogenetic Protein-2 was lyophilized from a 0.2 um filtered solution in 20mM AcOH pH 6.5.

The lyophilized protein is stable for at least 2 years from date of receipt at -20 degree C. Upon reconstitution, this cytokine can be stored in working aliquots at 2 degree - 8 degree C for one month, or at -20 degree C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.

Domain: Transforming growh factor beta. Host Note: Optimized DNA sequence encoding Human Bone Morphogenetic Protein-2 mature chain was expressed in Escherichia Coli.

Endotoxin: Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/ug (1EU/ug). Reconstitution: A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers. Molecular Weight Note: Native human Bone Morphogenetic Protein-2 is generated by the proteolytic removal of the signal peptide and propeptide, the molecule has a calculated molecular mass of approximately 13 kDa. Recombinant BMP-2 is a disulfide-linked homodimeric protein consisting of two 114 amino acid residue subunits. BMP2 migrates as an approximately 25 kDa protein under non-reducing conditions and as a 13 kDa protein under reducing conditions in SDS-PAGE.

Cytokines

BMPs are proteins that act to induce the differentiation of mesenchymal-type cells into chondrocytes and osteoblasts before initiating bone formation. They promote the differentiation of cartilage-forming cells and bone-forming cells near sites of fractures but also at ectopic locations. Some of the proteins induce the synthesis of alkaline phosphatase and collagen in osteoblasts. Some BMPs act directly on osteoblasts and promote their maturation while at the same time suppressing myogenous differentiation. Other BMPs promote the conversion of typical fibroblasts into chondrocytes and are capable also of inducing the expression of an osteoblast phenotype in non-osteogenic cell types. Intracellular signaling following engagement of receptors for some BMP proteins has been shown to involve the action of SMAD proteins. BMP-2 wild type binds to its cellular receptors via two distinct binding epitopes. The large epitope 1 is responsible for the high- affinity binding to the BMPR-IA receptor, the smaller epitope 2 provides the low-affinity binding to the receptor BMPR-II.

recombinant human bmp-2 enhances local bone formation in the lumbar spine of osteoporotic sheep . J Bone Joint Surg Br Proceedings, Sep 2009; 91-B: 436. remodeling of chromatin structure within the promoter is important for bmp-2 -induced fgfr3 expression . Nucleic Acids Res., Jul 2009; 37: 3897 - 3911. bmp-2 is a cost-effective therapy in grade iii open tibia fractures a health-economic assessment of the use bmp-2 in open tibia fractures for european health care systems . J Bone Joint Surg Br Proceedings, Mar 2009; 91-B: 155. activation of amp kinase and inhibition of rho kinase induce the mineralization of osteoblastic mc3t3-e1 cells through endothelial nos and bmp-2 expression . Am J Physiol Endocrinol Metab, Jan 2009; 296: E139 - E146. irbesartan attenuates ang ii-induced bmp-2 expression in human umbilical vein endothelial cells . Vascular Medicine, Aug 2008; 13: 239 - 245.

4557369

NP_001191.1

NM_001200.2

P12643

44,702 Da

Adipogenesis Pathway 198832!!Basal Cell Carcinoma Pathway 83113!!Basal Cell Carcinoma Pathway 525!!Cytokine-cytokine Receptor Interaction Pathway 83051!!Cytokine-cytokine Receptor Interaction Pathway 460!!Heart Development Pathway 198802!!Hedgehog Signaling Pathway 83063!!Hedgehog Signaling Pathway 474!!Id Signaling Pathway 198871!!Pathways In Cancer 83105

Function: Induces cartilage and bone formation. Subunit structure: Homodimer; disulfide-linked. Interacts with SOSTDC1. Interacts with GREM2, RGMA, RGMB and RGMC. Interacts with ASPN . By similarity. Ref.4. Subcellular location: Secreted. Tissue specificity: Particularly abundant in lung, spleen and colon and in low but significant levels in heart, brain, placenta, liver, skeletal muscle, kidney, pancreas, prostate, ovary and small intestine. Pharmaceutical use: Available under the name Infuse (Medtronic Sofamor Danek). Used for treating open tibial shaft fractures. Sequence similarities: Belongs to the TGF-beta family.

0.01 mg

220 USD